Scribeable vs DeepScribe:
Considering DeepScribe? Here is a factual look at how Scribeable differs — starting with the fact that DeepScribe's current public positioning is oncology-specific.
120+ clinicians · 2,600+ notes generated — real counters, no composites (scribeable.ai/transparency)
Why Physicians Switch from DeepScribe
No published pricing — deepscribe.ai routes every rate question to "Request a demo," so budgeting starts with a sales conversation
DeepScribe's current public site markets the product specifically for oncology workflows (OncoEMR, iKnowMed, Epic) — a different fit if you practice outside oncology
No self-serve signup; a demo request is required before any account access
A Specialty Pivot Worth Knowing About
DeepScribe's public site today describes itself as "ambient AI purpose-built to handle the complexity of oncology," with named integrations into OncoEMR, iKnowMed, and Epic and a stated adoption figure across community oncology centers. If your specialty isn't oncology, that's worth knowing before requesting a demo — Scribeable's 46 specialty templates and clinical calculators are built to work the same way across internal medicine, primary care, emergency medicine, psychiatry, surgery, and more.
Publish the Price or Don't
DeepScribe's own site offers no pricing page — the only CTA is "Request a demo." Scribeable publishes its rates: $39/month for Lite, $79/month for Pro, with a 14-day free trial and no credit card to start. You can see the price before you ever talk to anyone.
Capital Structure
DeepScribe's most recent publicly disclosed institutional funding round is a $30M Series A led by Index Ventures in 2022, with total disclosed funding reported around $60M. Scribeable has raised $0 in outside capital. Neither fact says anything about either product's quality — it's a difference in who each company answers to about long-term direction.
Same Patient. Same Encounter.
See why physicians say Scribeable notes are “actually usable” — with integrated risk scores, billing codes, and clinical reasoning that typical AI scribes simply don’t generate.
HPI
62 y/o male presents with chest pain for 2 hours. Substernal, pressure-like, radiating to left arm. Associated with diaphoresis and shortness of breath. Pain started while climbing stairs. Patient has history of HTN, DM2, and hyperlipidemia. Takes lisinopril, metformin, and atorvastatin. Denies recent illness or trauma.
Assessment & Plan
*Note examples are illustrative representations based on common AI documentation patterns. “Typical AI Scribe” represents composite characteristics of standard tools and does not depict any specific product. Patient scenarios are entirely fictional. Clinical notes should always be reviewed by a licensed provider.
AI Medical Scribe Note Quality Comparison
Scribeable produces clinically enriched notes with integrated risk calculators (HEART Score, CHA₂DS₂-VASc, Wells PE, PHQ-9, Caprini VTE), automated billing code optimization (E&M levels, HCC/RAF capture, CPT codes), dangerous diagnosis exclusion documentation, evidence-based prescribing citations, CMS compliance for operative reports, HEDIS care gap tracking, and MIPS quality measure documentation. Typical AI scribes produce basic notes without these advanced clinical features.
ED Chest Pain: 62-year-old male presenting with substernal chest pressure, diaphoresis, and exertional dyspnea
HPI: 62 y/o male presents with 2 hours of substernal chest pressure, rated 8/10, radiating to left arm and jaw. Onset during exertion (climbing stairs). Associated with diaphoresis and exertional dyspnea. Pressure-like quality, unrelieved by rest. No pleuritic component, no positional variation, no reproducibility with palpation. Risk factors: HTN (10 years), DM2 (8 years), hyperlipidemia, 30-pack-year smoking history (quit 5 years ago), family history of MI (father at age 58). Current medications: lisinopril 20mg daily, metformin 1000mg BID, atorvastatin 40mg daily. Denies cocaine use, recent immobilization, or prior VTE.
Assessment & Plan: 1. Acute Chest Pain — High-risk presentation HEART Score: 7 (High Risk) - History: moderately suspicious (2), EKG: non-specific ST changes (1), Age: >65 (2), Risk factors: ≥3 (2), Troponin: pending initial (0) - Risk stratification: >12% 6-week MACE event rate → full ACS workup - Serial troponins q3h, 12-lead EKG (initial + repeat at 60 min) - ASA 325mg PO administered, heparin drip per ACS protocol - Cardiology consulted for probable cath lab activation Dangerous Diagnosis Exclusion: - STEMI: No ST elevation on initial EKG — serial monitoring - Aortic dissection: No tearing quality, no pulse differential, no mediastinal widening on CXR - PE: Low pretest probability (Wells PE: 1.5) — no immobilization, no prior VTE, no hemoptysis 2. Hypertension — BP 168/94 on arrival, improved to 142/88 post-NTG - Continue home lisinopril, recheck prior to disposition 3. DM2 — Glucose 186 on arrival - Hold metformin (contrast exposure risk), sliding scale insulin PRN
Cardiology Consult: 71-year-old female with new-onset atrial fibrillation and decompensated heart failure
HPI: 71 y/o female with known HFrEF (EF 35% on TTE 6 months ago), HTN, DM2, and CKD Stage 3a (baseline Cr 1.4), consulted for new-onset atrial fibrillation with RVR. Progressive exertional dyspnea (NYHA II → IV over 2 weeks), 3-pillow orthopnea (new), PND, and 4+ pitting edema to knees bilaterally. Weight gain of 8 lbs over 2 weeks. Triggers explored: dietary indiscretion (holiday meals), medication non-adherence (ran out of furosemide 10 days ago). No prior AF history, no palpitations previously. Denies chest pain, syncope, or presyncope.
Assessment & Plan: Reason for Consult: New-onset atrial fibrillation with RVR in setting of acute decompensated HFrEF. Requesting Service: Internal Medicine (Dr. Patel) 1. New-onset Atrial Fibrillation with RVR CHA₂DS₂-VASc Score: 5 (Female sex, age ≥75, HTN, DM, HF) - Stroke risk: 6.7%/year → strong anticoagulation indication - Rate control: avoid diltiazem (negative inotropy in HFrEF) → amiodarone 150mg IV bolus then 1mg/min × 6h - Anticoagulation: apixaban 5mg BID (preferred over warfarin given age + fall risk) - TEE prior to any cardioversion attempt if AF duration uncertain - HAS-BLED: 2 (HTN, age) — acceptable bleeding risk 2. Acute Decompensated Heart Failure (ADHF) NYHA Functional Class: IV (dyspnea at rest) - IV furosemide 80mg BID (2.5× home oral dose), net negative 1-1.5L/day - Carvedilol held (acute decompensation), restart when euvolemic - Add sacubitril/valsartan when stable (PARADIGM-HF indication: EF ≤40% on ACEi) - BNP trend: 1,840 → monitor for response to diuresis 3. CKD Stage 3a — Cr 1.4 (baseline), monitor with aggressive diuresis - KDIGO risk: moderate — monitor Cr/K daily with diuresis
Operative Note: Right total knee arthroplasty in 68-year-old male with severe tricompartmental osteoarthritis
Operative Note: Preoperative Diagnosis: Right knee severe tricompartmental osteoarthritis (Kellgren-Lawrence Grade IV) Postoperative Diagnosis: Same Procedure: Right total knee arthroplasty Surgeon: Dr. James Morrison (attending — present and scrubbed for entire case) Assistant: Dr. Chen (PGY-4) Anesthesia: Spinal with sedation (Dr. Rivera) Implants: Smith & Nephew Legion CR, Size 5 femoral / Size 4 tibial / 10mm poly insert EBL: 150 mL Tourniquet Time: 62 minutes (pneumatic, 275 mmHg) Specimens: Femoral and tibial bone cuts — to pathology Complications: None Findings: Severe tricompartmental degenerative changes with exposed subchondral bone medially, grade III chondromalacia laterally, intact PCL
Post-Operative Plan: 1. Weight Bearing: WBAT right LE with front-wheeled walker 2. DVT Prophylaxis: Enoxaparin 40mg SQ daily × 14 days + mechanical (SCDs while inpatient) 3. Pain: Multimodal — scheduled acetaminophen 1g Q6h, meloxicam 15mg daily, tramadol 50mg Q6h PRN (max 14 days) 4. Antibiotics: Ancef 2g IV × 24h post-op 5. PT: Initiate POD0 PM — CPM machine, active/passive ROM, gait training 6. Follow-up: 2 weeks (staple removal + wound check), 6 weeks (X-ray + ROM assessment) 7. VTE Risk: Caprini Score 7 (High Risk) — extended pharmacologic prophylaxis indicated
Primary Care: 55-year-old female Medicare Advantage patient with DM2, HTN, depression, and overdue preventive care
HPI: 55 y/o female Medicare Advantage patient presenting for chronic disease management follow-up. Last visit 3 months ago. Diabetes (DM2, 8 years): A1c 8.2% (up from 7.6%), reports adherence but dietary indiscretion during holidays. Home glucose logs show fasting 140-180 range. No hypoglycemic episodes. Denies polyuria, polydipsia, vision changes, or foot numbness. Last diabetic eye exam: 14 months ago (overdue). Last podiatry visit: never. Hypertension (12 years): Home BP readings averaging 135-145/85-90. Taking lisinopril 20mg daily consistently. Depression (MDD, recurrent): PHQ-9 score today: 14 (moderately severe). Persistent low mood, anhedonia, poor sleep (initial insomnia), decreased concentration. On sertraline 50mg × 6 months with partial response. Denies SI/HI, denies alcohol or substance use. Columbia Suicide Severity: negative for ideation and behavior.
Assessment & Plan: 1. DM2, Uncontrolled (A1c 8.2%) — HCC 19 - Add empagliflozin 10mg daily (SGLT2i — CV and renal benefit, EMPA-REG OUTCOME indication) - Continue metformin 500mg BID (not escalating given GI intolerance history) - Diabetic eye exam referral (overdue 2 months — HEDIS measure) - Podiatry referral for initial foot exam - Recheck A1c in 3 months, target <7% 2. Hypertension, Suboptimally Controlled — HCC (when with CKD/DM) - BP today 138/86 — above target of <130/80 (ACC/AHA for DM patients) - Increase lisinopril to 40mg daily - Home BP log review in 4 weeks 3. Major Depressive Disorder, Recurrent, Moderate — HCC 59 - PHQ-9: 14 (moderately severe) — partial response to sertraline 50mg - Increase sertraline to 100mg daily - Safety plan reviewed, crisis line provided (988) - Follow-up in 4 weeks, recheck PHQ-9 - If inadequate response → consider augmentation or psychiatry referral 4. Preventive Care Gaps Addressed: - Mammogram ordered (last: 26 months ago — HEDIS BCS measure) - Colonoscopy referral (age 55, average risk, never screened — HEDIS COL) - Tobacco screening: former smoker, quit 3 years — MIPS measure 226 - Annual flu vaccine administered today — MIPS measure 110
Feature-by-Feature Comparison
Pricing & Access
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Published, self-serve pricingdeepscribe.ai has no pricing page; the only CTA is "Request a demo" | ||
| Sign up without a sales callDeepScribe requires a demo request before any account access | ||
| Built for every specialtydeepscribe.ai now markets itself specifically as oncology-focused ambient AI (OncoEMR, iKnowMed, Epic) |
Ownership & Capital
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Clinician-owned, portable accountDeepScribe positions itself for oncology centers and community-oncology enterprise adoption | ||
| Zero outside capital (bootstrapped)DeepScribe's most recent disclosed institutional round is a $30M Series A led by Index Ventures (2022); total disclosed funding is reported around $60M |
Clinical Intelligence
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Deterministic clinical calculators (236, code-scored)Not stated on deepscribe.ai as of Jul 2026 | ||
| Two-stage AI verification (draft + clarification pass)Not stated on deepscribe.ai as of Jul 2026 |
Competitor facts on this page are sourced to each company's own public site and verified as of 2026-07-11; see page source for the full citation list. Competitor capabilities and pricing may change after that date.
Pricing Comparison
DeepScribe
Not published — "Request a demo" only
Contact for pricing
Scribeable's rates are on the pricing page today. DeepScribe's public site has no pricing page and no self-serve tier; third-party per-provider estimates exist but are not confirmed by DeepScribe itself, so they are not repeated here.
Other AI scribes optimize for time to first draft. Scribeable optimizes for time to signed note, with a verification pass built in before you sign.
5.0 on the App Store120+
Clinicians on board
2,600+
Patient notes generated
Which Should You Choose?
Choose DeepScribe if you...
- Oncology practices specifically evaluating an ambient AI built around OncoEMR or iKnowMed integration
- Community oncology centers already in DeepScribe's stated adoption base
- Organizations with an existing DeepScribe enterprise relationship
Frequently Asked Questions
Compare Other Alternatives
vs Dragon Copilot
Considering Microsoft Dragon Copilot, the product formerly sold as Nuance DAX? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and who each company answers to.
vs Nabla
Considering Nabla? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and the capital structure behind the "we don't train on your data" promise both companies make.
vs Abridge
Considering Abridge? Here is a factual look at how Scribeable differs — on pricing transparency, who owns the account, and the capital structure behind the platform.
Start Your 14-Day Free Trial — No Credit Card
Compare Scribeable to DeepScribe on your own terms. Generate your first note in under 5 minutes.
Scribeable vs DeepScribe - AI Medical Scribe Comparison
Considering DeepScribe? Here is a factual look at how Scribeable differs — starting with the fact that DeepScribe's current public positioning is oncology-specific.
Why Physicians Switch from DeepScribe
- No published pricing — deepscribe.ai routes every rate question to "Request a demo," so budgeting starts with a sales conversation
- DeepScribe's current public site markets the product specifically for oncology workflows (OncoEMR, iKnowMed, Epic) — a different fit if you practice outside oncology
- No self-serve signup; a demo request is required before any account access
Why Choose Scribeable Over DeepScribe
- $39-79/month, published on the pricing page — no demo request required to see a rate
- Self-serve signup across any specialty — not built around one disease area
- Clinician-owned, portable account that moves with you across employers
- 236 clinical calculators, code-scored and validated, inside every note
- A two-stage AI pipeline: a draft pass, then a separate verification pass that asks a clarification question instead of guessing
- 14-day free trial (or 15 notes, whichever comes first), no credit card required
A Specialty Pivot Worth Knowing About
DeepScribe's public site today describes itself as "ambient AI purpose-built to handle the complexity of oncology," with named integrations into OncoEMR, iKnowMed, and Epic and a stated adoption figure across community oncology centers. If your specialty isn't oncology, that's worth knowing before requesting a demo — Scribeable's 46 specialty templates and clinical calculators are built to work the same way across internal medicine, primary care, emergency medicine, psychiatry, surgery, and more.
Publish the Price or Don't
DeepScribe's own site offers no pricing page — the only CTA is "Request a demo." Scribeable publishes its rates: $39/month for Lite, $79/month for Pro, with a 14-day free trial and no credit card to start. You can see the price before you ever talk to anyone.
Capital Structure
DeepScribe's most recent publicly disclosed institutional funding round is a $30M Series A led by Index Ventures in 2022, with total disclosed funding reported around $60M. Scribeable has raised $0 in outside capital. Neither fact says anything about either product's quality — it's a difference in who each company answers to about long-term direction.
Feature Comparison: Scribeable vs DeepScribe
Pricing & Access
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Published, self-serve pricing | Yes | No |
| Sign up without a sales call | Yes | No |
| Built for every specialty | Yes | No |
Ownership & Capital
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Clinician-owned, portable account | Yes | No |
| Zero outside capital (bootstrapped) | Yes | No |
Clinical Intelligence
| Feature | Scribeable | DeepScribe |
|---|---|---|
| Deterministic clinical calculators (236, code-scored) | Yes | Partial |
| Two-stage AI verification (draft + clarification pass) | Yes | Partial |
Pricing Comparison
Scribeable: Free tier, then $39-79/month, published
DeepScribe: Not published — "Request a demo" only
Scribeable's rates are on the pricing page today. DeepScribe's public site has no pricing page and no self-serve tier; third-party per-provider estimates exist but are not confirmed by DeepScribe itself, so they are not repeated here.
Which Should You Choose?
If you practice outside oncology, DeepScribe's current public positioning is built around a different specialty than yours — worth knowing before you request a demo. If pricing transparency and an account that stays yours across jobs matter, that's what Scribeable is built around. If you're specifically evaluating an oncology-focused ambient AI with OncoEMR or iKnowMed integration, DeepScribe's current focus may be the more direct fit.
Frequently Asked Questions
Does DeepScribe publish its pricing?
No. DeepScribe's website has no pricing page — the only conversion path is "Request a demo." Scribeable's pricing page lists $39/month (Lite) and $79/month (Pro) directly, no demo required.
Is DeepScribe built for my specialty?
As of July 2026, DeepScribe's own site markets it specifically as "ambient AI purpose-built to handle the complexity of oncology," with named integrations into OncoEMR, iKnowMed, and Epic. If you practice outside oncology, confirm current specialty support directly with DeepScribe before requesting a demo. Scribeable supports 46 specialties with dedicated templates.
Is DeepScribe VC-backed?
Yes. DeepScribe's most recent publicly disclosed institutional round is a $30M Series A led by Index Ventures (2022), with total disclosed funding reported around $60M across its history (source: TechCrunch's coverage of the round). Scribeable has raised $0 in outside capital.
Can I try Scribeable before requesting a DeepScribe demo?
Yes. Scribeable is self-serve: start a 14-day free trial (or 15 notes, whichever comes first) with no credit card at dashboard.scribeable.ai/signup. No demo request is required to start.
Sources
DeepScribe's public site has no pricing page; the only CTA is "Request a demo."
DeepScribe markets itself as "ambient AI purpose-built to handle the complexity of oncology," with OncoEMR, iKnowMed, and Epic integration.
DeepScribe raised a $30M Series A led by Index Ventures, with participation from Bee Partners, Stage 2 Capital, and 1984 Ventures.
Scribeable pricing: Lite $39/mo, Pro $79/mo.
Explore More
Discover how Scribeable can help your practice with AI-powered clinical documentation